Concepedia

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Javier Cortés, Véronique Dièras, Jungsil Ro, Jérôme Barrière, Thomas Bachelot, Sara A. Hurvitz, Émilie Le Rhun, Marc Espié, Sung‐Bae Kim, Andreas Schneeweiß,

The Lancet Oncology · 2015 · 129 citations · 24 references

DOIFull text

Open access

Concepts

References

24

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

, , +17

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text

, , +11

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Flavio Solca, G. Dahl, Andreas Zoephel et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 867 citations

, , +16

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

Eli Dijkers, Thijs H. Oude Munnink, Jos G. W. Kosterink et al. · Clinical Pharmacology & Therapeutics · 2010 · 807 citations

, , +17

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology · 2012 · 742 citations

, , +16